A recent study published in The American Journal of Gastroenterology has revealed a significant association between GLP-1RAs and lower quality of bowel prep for colonoscopies.
While GLP-1 agonists are known for their effective weight loss results, they come with significant drawbacks, including loss of lean muscle mass. Taldefgrobep alfa, a myostatin inhibitor licensed from Bristol Myers Squibb, stands apart by targeting not just fat loss but also muscle preservation.
Eli Lilly is adopting a unique marketing approach for tirzepatide, known as Mounjaro for type 2 diabetes and Zepbound for weight loss.
